TMO (Thermo Fisher Scientific Inc.) Trailing twelve months financial, business summary

Thermo Fisher Scientific Inc.

TMO

662.06 (0.00%) 0.00

Market cap

$244.79(B)

Earnings date

Oct-21-2026

Sector

Health Care

Industry

Life Sciences Tools and Services

Thermo Fisher Scientific Inc. provides life sciences solutions analytical instruments specialty diagnostics and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions Analytical Instruments Specialty Diagnostics and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents instruments and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments consumables software and services for pharmaceutical biotechnology academic government environmental and other research and industrial markets as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits calibrators controls protein detection assays and instruments; immunodiagnostic offerings comprising developing manufacturing and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy asthma and autoimmune diseases; microbiology offerings such as dehydrated and prepared culture media collection and transport systems instrumentation and consumables to detect pathogens in blood diagnostic and rapid direct specimen tests quality-control products and associated products; transplant diagnostics products including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products research and safety market channel and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham Massachusetts.

EV: $308.92(B)

Total Equity: $52.81(B)

Debt/Equity: 0.81

Dividend/share: $1.8

Div. yield: 0.27%

P/E: 35.54

Forward P/E: 26.35

P/FCF: 33.45

P/S: 5.34

P/B: 4.65

EPS: $18.6

EPS (fwd): $25.1

FCF/share: $19.8

Revenue/share: $123.9

Book value/share: $142.5

ROIC: 7.7%

ROA: 6.5%

ROE: 13.1%

Margins: Gross | Op. | Net

41.0% | 18.4% | 15.0%

0.0%of Portfolio

My holdings

Day change

Total change

Overview Valuation Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools All

PEvaluation

40%

$399

Based on a fair P/E of 15.1x and
forward EPS of $26.44

Valuation summary

Min—

Max—

Average—

Median—

Valuation comparison

Quality checklist score

5/8

Based on your selected metrics.

5Y Shares Out Change < 0% Debt/Equity < 1 Current Ratio > 1 Net Margin > 10% Est. EPS Growth > 5%

ROIC > 10% Quick Ratio > 1 Past Net Income CAGR > 0%

TTM Financials

Income (TTM)

Revenue$46.34(B)

Gross profit$18.99(B)

EBITDA$11.74(B)

Net income$6.97(B)

Gross margin41.0%

Operating margin18.4%

Net margin15.0%

Shares outstanding369.75(M)

Balance sheet

Total assets$113.17(B)

Current assets$23.36(B)

Total liabilities$60.37(B)

Current liabilities$15.07(B)

Cash & Short-term inv.$4.06(B)

Long-term debt$38.92(B)

Total intangibles$73.44(B)

PP&E$10.76(B)

Cash flow (TTM)

FCF$7.32(B)

CapEx$-1.70(B)

Dividends paid$-662.00(M)

Stock issued$0

Stock repurchased$-5.00(B)

Stock-based comp.$319.00(M)

Debt issued$11.64(B)

Debt repaid$-3.68(B)

Per share data (TTM)

Price

$662

Income

Revenue

$124•5.3x|18.7%

Gross profit

$51.4•12.9x|7.8%

Earnings (EPS)

$18.6•35.5x|2.8%

Cash flow

FCF

$19.8•33.5x|3.0%

Stock-based comp.

$0.86•767.4x|0.1%

CapEx

$4.58•144.4x|0.7%

Dividend

$1.80•367.8x|0.3%

Balance sheet

Total assets

$306•2.2x|46.2%

Total liabilities

$163•4.1x|24.7%

Book value

$142•4.6x|21.5%

Cash & ST inv.

$11.0•60.2x|1.7%

Debt

$105•6.3x|15.9%

Forward earnings

EPS FY+1

$25.1•26.3x|3.8%

EPS FY+2

$27.5•24.0x|4.2%

EPS FY+3

$30.5•21.7x|4.6%

EPS FY+4

$34.2•19.4x|5.2%

EPS FY+5

$37.8•17.5x|5.7%

Forward FCF

FCF FY+1

$19.1•34.6x|2.9%

FCF FY+2

$24.7•26.8x|3.7%

FCF FY+3

$26.4•25.1x|4.0%

FCF FY+4

$28.5•23.3x|4.3%

FCF FY+5

$31.4•21.1x|4.7%

Summary

	Low	Avg	High	#
FY+1	25.0	25.1	25.4	27
FY+2	26.5	27.5	29.1	28
FY+3	28.8	30.5	32.3	18
FY+4	33.1	34.2	35.0	5
FY+5	36.9	37.8	39.5	3

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
Low Mid High
Terminal Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Terminal Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Exit FCF Multiple
Low Mid High
Discount Rate

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Low Mid High
Final Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
Low Mid High
Final P/E
Low Mid High
Discount Rate

Market cap

Earnings date

Category

Sector

Industry

TTM Financials

Income (TTM)

Balance sheet

Cash flow (TTM)

Per share data (TTM)

Summary

PEvaluation

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: Medium

EPS Estimates

Analyst Price Targets

Analyst Recommendations

2-stage DCF

Discounted Cash Flow

Free cash flow estimates:

Discounted Cash Flow (exit mult.)

Free cash flow estimates:

Dividend Discount Model

EPS Growth

Revenue Growth Valuation

Peter Lynch Fair Value

Graham Formula

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
Low Mid High
Final Net Margin
Low Mid High
Final P/E Ratio
Low Mid High
Discount Rate

Earnings Per Share
EPS Growth (7-10 years)
Low Mid High
Government Bond Rate